Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Adaptimmune Therapeutics (ADAP) has issued an announcement.
Adaptimmune Limited and Galapagos NV have embarked on a promising collaboration, initiating a clinical trial to test a novel T-cell therapy for head & neck cancer. The agreement nets Adaptimmune $70 million upfront plus potential milestone payments up to $465 million and royalties on future sales. While Galapagos gains exclusive licensing options, Adaptimmune retains rights for its therapy in treating ovarian cancer. This strategic partnership could revolutionize cancer treatment and offers financial upside for both companies.
For detailed information about ADAP stock, go to TipRanks’ Stock Analysis page.
